Healthcare Industry News: cardiac monitor
News Release - December 9, 2013
ICU Medical Launches the ChemoLock(TM) Needlefree Closed System Transfer Device (CSTD) at the American Society of Health-System Pharmacists (ASHP) Midyear MeetingChemoLock Protects Patients and Caregivers From Exposure to Hazardous Drugs and is the First and Only Needlefree CSTDto Receive FDA Classifications for Both Pharmacy Preparation (ONB) and Patient Administration (FPA)
ORLANDO, Fla., Dec. 9, 2013 -- (Healthcare Sales & Marketing Network) -- ICU Medical, Inc. (ICUI) today announced that will formally launch the ChemoLock(TM) needlefree closed system transfer device (CSTD) at the American Society of Health-System Pharmacists (ASHP) Midyear Meeting and Exhibition in Orlando December 9-11, 2013. ChemoLock is the first and only needlefree CSTD to receive United States Food and Drug Administration (FDA) 510(k) clearance for pharmacy applications (product code ONB), as well as patient administration applications (product code FPA).
The ChemoLock system was designed to provide a new standard of safety for hazardous drug preparation, transportation, administration and disposal. The system prevents the escape of hazardous drug or vapor concentrations outside the system, blocks the transfer of bacteria and other environmental contaminants into the system, and eliminates needlestick injuries while keeping patients and clinicians safe from hazardous drug exposure
"ChemoLock is an intuitive needlefree system to keep pharmacy and nursing staffs and their patients safe from exposure to hazardous drugs," explained ICU Medical Chairman Dr. George Lopez. "By preventing the transfer of environmental contaminants into the system and blocking the escape of drug or vapor concentrations outside the system, ChemoLock will keep clinicians and patients safe from exposure to a wide range of hazardous drugs—including those used in chemotherapy—while maintaining the sterility of the drugs themselves."
The ChemoLock system consists of easy to use needlefree components that connect with an audible click, cannot be deactivated, and will passively aid in preventing both needlestick injuries and the exposure cytotoxic medications. No complex assembly is required prior to usage and the system remains completely closed throughout the entire safe handling process—including preparation, transportation, administration, and disposal—assuring both patient and caregiver safety as well as the sterility of the prepared medication.
"ChemoLock is a mechanically and microbiologically closed needlefree system that is safe, intuitive, and easy to use during every step of the hazardous drug handling process, helping assure compliance with industry safe-handling guidelines," explained Robert Houde, RPh, Director of ICU Medical's Oncology Division. "It offers significant advantages over competitive products on the market, and is a perfect complement to our current product line, which includes the ChemoClave® CSTD and Closed System product line and the DianaTM hazardous drug compounding system—which will also be shown at ASHP. No other company can offer customers the range of safe handling solutions that we do."
The full line of ICU Medical safe handling solutions can be seen in Booth #713 at the ASHP meeting being held in the Orange County Convention Center in Orlando December 9-11, 2013.
Contact: Tom McCall
Vice President, Chief Marketing Officer
About ICU Medical, Inc.
ICU Medical, Inc. develops, manufactures and sells innovative medical devices used in vascular therapy, oncology and critical care applications. ICU Medical's products improve patient outcomes by helping prevent bloodstream infections and protecting healthcare workers from exposure to infectious diseases or hazardous drugs. The company's complete product line includes custom IV systems, closed delivery systems for hazardous drugs, needlefree IV connectors, catheters and cardiac monitoring systems. ICU Medical is headquartered in San Clemente, California. More information about ICU Medical, Inc. can be found at www.icumed.com.
Source: ICU Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.